Evogene

Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation

Retrieved on: 
Tuesday, February 6, 2024
Research, Bacteria, Evogene, Probiotic, Human body, EVP, Computational biology, Health, Business

BOSTON and REHOVOT, Israel, Feb. 6, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across multiple market segments, and Verb Biotics LLC., a microbiome health ingredient company whose mission is to improve human health, entered into a collaboration agreement that will focus on the development of new strains of probiotic bacteria, which produce a highly sustainable quantity of microbial metabolites that improve human health and vitality. The collaboration will focus on identifying and enhancing the currently unknown genetic pathways in microbes that support the production of novel metabolites, using Evogene's MicroBoost AI tech-engine and Verb Biotics' extensive accumulated knowledge in the field of the microbiome.

Key Points: 
  • The probiotics market is expected to double and reach approximately $114 billion by 2031 from approximately $55 billion in 2022[i].
  • "Partnering with Evogene equips Verb Biotics with a powerful edge to revolutionize microbiome-driven health solutions.
  • By leveraging Evogene's technology, we further streamline and de-risk our innovation pathway, prioritizing function-first approaches for optimal microbiome health", says Noah Zimmerman, CTO at Verb Biotics.
  • Together with Verb Biotics, we aim to drive substantial progress in probiotics innovation and to stretch the boundaries of what can be achieved in this field."

Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

Retrieved on: 
Tuesday, December 19, 2023
Research, Biopolymer, Biofuel, Evogene, Business development, Growth, EVP, Management

REHOVOT, Israel, Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry.

Key Points: 
  • Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry.
  • Casterra has also significantly expanded its team, including experts in research and development, seed production, and customer support.
  • Mr. Ofer Haviv, Casterra's Chairman and Evogene's CEO, commented, "As Casterra experiences significant growth, I am delighted to welcome Mr. Yoash Zohar as its new CEO.
  • Mr. Yoash Zohar expressed enthusiasm about the new role, stating, "I am honored to join Casterra as CEO during this pivotal growth phase.

Evogene Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 17, 2023
Shekel, Computational biology, Operating cost, Therapy, Irritable bowel syndrome, Seed, Marketing, Renal cell carcinoma, Farmer, Non-small-cell lung cancer, Canadian Food Inspection Agency, Clinical trial, Rambam Health Care Campus, Generator, CFIA, Fruit, Irritation, Conference call, Protein, Pesticide, International use of the U.S. dollar, Patient, IBS, Melanoma, Algorithm, TASE, AG, Visceral pain, Webcast, BMS, Conference, Safety, Automation, Pharmaceutical industry, Cryptocurrency, Video game, Broadcasting, New York University, Corteva, Evogene, Canonical

REHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.

Key Points: 
  • REHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.
  • Ofer Haviv, Evogene's President and Chief Executive Officer, stated: "The second quarter of 2023 marked a period of remarkable achievements for the Evogene group.
  • Revenues for the second quarter of 2023 were approximately $654 thousand compared to approximately $312 thousand in the same period the previous year.
  • This difference was mainly due to the U.S. Dollar and Shekel exchange rate differences between periods, a decrease in marketable securities value in the second quarter of 2022 and an increase in interest income during the second quarter of 2023.

Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Retrieved on: 
Tuesday, July 25, 2023
Computational biology, Probability, Protein, Therapy, Target protein, Agriculture, Research, Pesticide, Algorithm, TASE, CPO, Fine chemical, Evogene

REHOVOT, Israel, July 25, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, is proud to announce the latest addition to its ChemPass AI tech-engine – a breakthrough technology for target-protein discovery. The integration of TargetSelector, a new application that streamlines target-protein discovery for active molecule identification, assists researchers in finding suitable target proteins for new products while reducing development time, resources and most importantly, increasing the probability of success.

Key Points: 
  • Proteins play a fundamental role in a wide array of biological processes and serve as the primary targets for developing innovative therapeutics, ag-chemical, ag-biological, and other life science solutions.
  • The precise identification of these protein targets is pivotal in advancing research and discovery across various domains, including pharmaceuticals, agriculture, and environmental applications.
  • The challenge of finding a target-protein that is novel, safe, and druggable from the thousands of proteins in a relevant organism is enormous.
  • "ChemPass AI tech-engine is a cutting-edge platform for the identification of small molecules.

Casterra Announces Additional $2.2 Million of Purchase Orders to Supply Castor Seeds for New African Territories

Retrieved on: 
Monday, July 3, 2023
Edible, Plant, Growth, Generator, Biofuel, Evogene, Seed, Carbon, TASE, Vegetable oil

REHOVOT, Israel, July 3, 2023 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company and a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ: EVGN) (TASE: EVGN), today announced additional $2.2 million of purchase orders to supply castor seeds during 2023, for new African territories. Casterra's castor seeds, developed with Evogene's GeneRator AI Tech Engine, will be used to grow Castor to produce oil for sustainable biofuel. Casterra's high-yield, high-oil castor seed varieties are optimized for biofuel production to support the growing sustainable energy market.

Key Points: 
  • REHOVOT, Israel, July 3, 2023 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company and a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ: EVGN) (TASE: EVGN), today announced additional $2.2 million of purchase orders to supply castor seeds during 2023, for new African territories.
  • Casterra's castor seeds, developed with Evogene's GeneRator AI Tech Engine, will be used to grow Castor to produce oil for sustainable biofuel.
  • Casterra's high-yield, high-oil castor seed varieties are optimized for biofuel production to support the growing sustainable energy market.
  • Casterra, as Evogene's subsidiary, spearheads the development of proprietary high-yield castor varieties leveraging the company's cutting-edge computational biology technologies.

Evogene Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 18, 2023
Computational biology, Operating cost, Food, Therapy, Seed, IBD, Marketing, ICL, Clinical trial, Generator, SHC, Irritable bowel syndrome, Fruit, Inflammatory bowel disease, Castor oil, EPA, Corteva, United States Environmental Protection Agency, IBS, Herbicide, TASE, AG, EVF, Growth, EIC, THC, Horizon, CO2, Automation, Pharmaceutical industry, Sewage treatment, Rare-earth element, Fine chemical, Agriculture, Airline, Drug, EU, Evogene, Canonical

REHOVOT, Israel, May 18, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the first quarter period ending March 31, 2023.

Key Points: 
  • REHOVOT, Israel, May 18, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the first quarter period ending March 31, 2023.
  • Cash position: Evogene maintains a solid financial position for its activities with approximately $28.8 million in consolidated cash, cash equivalents, and marketable securities as of March 31, 2023.
  • Sales and marketing expenses were approximately $800 thousand for the first quarter of 2023, compared to approximately $908 thousand in the same period the previous year.
  • General and administrative expenses were approximately $1.5 million in the first quarter of 2023, compared to approximately $1.6 million in the same period in the previous year.

Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance

Retrieved on: 
Tuesday, May 9, 2023
Computational biology, Business development, Food, EU, Microbiology, Climate, Max Planck Institute for Terrestrial Microbiology, Seed, Atmosphere, Agricultural Academy, Agriculture, Max Planck Society, EVP, Research, Division of Industrial Hygiene, Risk, Carbon, Science, Biochemistry, Plant, Chemistry, European Horizons, Climate change, Metabolism, TASE, Engineering, European, Water, Max Planck, EIC, In Society, Horizon, Biomass, Water resources, Synthetic biology, Renewable energy, Evogene

REHOVOT, Israel, May 9, 2023 /PRNewswire/ -- The Ag-Seed Division of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments has announced that it has been granted a prestigious EU Horizon grant of €1.2 million, to support the creation of oil-seed crops that have high carbon-dioxide assimilation and enhanced drought tolerance. The project, Crop4Clima, has an overall budget of €2.5 million and is expected to be executed over 32 months. This grant follows the successful completion of the FutureAgriculture Consortium's proof-of-concept in 2021, which demonstrated the potential for increased agricultural productivity and environmental sustainability.

Key Points: 
  • In addition, it enables the saving of scarce water resources and improved plant tolerance against drought conditions.
  • Results showed increased carbon-dioxide assimilation by plants, combined with improved drought tolerance and plant productivity.
  • The €1.2 million grant awarded to Evogene will cover Evogene's estimated costs to participate in this program.
  • The proof of concept is further validated by our consortium winning the prestigious European Horizon grant, whose goal is sustainable agriculture.

Plantis Licenses Two of Canonic's Proprietary Cannabis Varieties to Expand its Offerings in the Israeli Market

Retrieved on: 
Tuesday, May 2, 2023
Smell, Partnership, Altitude, Genetics, Atmosphere, Marketing, Breeding, Water quality, Generator, Terpene, Sunlight, Marker beacon, Patient, Algorithm, TASE, Artificial intelligence, THC, Drug, Medicinal plants, Evogene, Canonical, Cannabis

The two new varieties were developed by Canonic using proprietary sets of novel genetic markers targeting unique differentiation factors.

Key Points: 
  • The two new varieties were developed by Canonic using proprietary sets of novel genetic markers targeting unique differentiation factors.
  • The new medical cannabis products made from these two varieties, will expand Plantis' product offering and cater to a broader range of customers in Israel.
  • Plantis is a medical cannabis company with the aim of improving, enhancing, and refining the treatment options with medical cannabis.
  • We look forward to continuing to expand our relationship with Plantis over the coming years."

Casterra Announces Agreement with World Leading Energy Company to Cultivate its Castor Varieties at Commercial Scale

Retrieved on: 
Thursday, January 19, 2023
AG, Carbon, Ricinus, Viscosity, Toxicity, Growth, Castor oil, Evogene, Biofuel, TASE, Vegetable oil, Agriculture

REHOVOT, Israel, Jan. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), the integrated castor cultivation solution company and a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), announced today that it has entered into an agreement with one of the world's leading energy companies, whereby Casterra will provide its unique castor varieties and its broad know-how in cultivation of castor at a commercial scale for biofuel production.

Key Points: 
  • Under the framework of the agreement, the initial focus is the purchase agreement of castor seed varieties from Casterra for growing castor in specific African territories and the provision of technical support.
  • The agreement also allows for the potential for long-term cooperation in castor cultivation between this customer and Casterra, with the potential for expansion into additional territories on the African continent.
  • Casterra's mission is to provide the most genetically advanced castor bean seed varieties, tailored to humanity's eco-friendly energy needs of today, with a complete comprehensive ag-service solution to castor cultivators and manufacturers.
  • This new agreement has significant potential for future growth and strengthens our position in the castor biofuel market."

Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics

Retrieved on: 
Monday, December 26, 2022
Inflammatory bowel disease, Like a Boss (film), TASE, SHC, Patient, CPB, Computational biology, Weizmann Institute of Science, Risk, PRISM, IBD, Probability, FDA, Yangtze Delta, Clinical trial, Computation, Therapy, Generator, Holding, AG, Doctor of Philosophy, Politics of Shanghai, GMP, Research, Artificial intelligence, Senior advisor, Pharmaceutical industry, Antibiotics, Management, Evogene

REHOVOT, Israel, Dec. 21, 2022 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the signing of a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities.

Key Points: 
  • The fund's goal is investment in early stage and best-in-class innovators with a pipeline of therapies for improving the lives and long-term outcome of patients.
  • The fund is managed by SIIC Capital, with Shanghai Pharma as one of the founding and strategic Limited Partners.
  • The financing round will enable Biomica to forge ahead, developing its pipeline of microbiome-based therapeutics.
  • Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene.